TVTX – travere therapeutics, inc. (US:NASDAQ)

News

Travere Therapeutics (TVTX) had its price target lowered by JPMorgan Chase & Co. from $44.00 to $41.00. They now have an "overweight" rating on the stock.
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli [Yahoo! Finance]
Piper Sandler Increases Target Price for Travere Therapeutics (TVTX) [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX): A Bull Case Theory [Yahoo! Finance]
Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms [Seeking Alpha]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com